JessLi personal page - To The Moon

JessLi

JessLi

No personal profile

7Follow

3Followers

0Topic

0Badge

2021-09-13

You really shouldn't spread false news

Sorry, the original content has been removed

2021-09-02

$Splunk(SPLK)$ To the MOON

2021-06-15

$HMG/Courtland Properties(HMG)$ just IPO? No volume but so much change

2021-06-15

Buy or nor

Ocugen Secures Manufacturing Partnership for US Production of COVID-19 Vaccine Candidate, COVAXIN™

2021-06-11

$Annovis Bio, Inc.(ANVS)$ lets go to 100 today!

2021-06-08

$Clean Energy Fuels(CLNE)$ time to go

2021-06-07

$Annovis Bio, Inc.(ANVS)$ hoi where is my 80

Go to Tiger App to see more news

{"i18n":{"language":"en_US"},"userPageInfo":{"id":"3582675299947074","uuid":"3582675299947074","gmtCreate":1620383036333,"gmtModify":1621649405993,"name":"JessLi","pinyin":"jessli","introduction":"","introductionEn":null,"signature":"","avatar":"https://static.tigerbbs.com/4825402e4b1dc6309048cc8a1269b652","hat":null,"hatId":null,"hatName":null,"vip":1,"status":2,"fanSize":3,"headSize":7,"tweetSize":15,"questionSize":0,"limitLevel":999,"accountStatus":4,"level":{"id":3,"name":"书生虎","nameTw":"書生虎","represent":"努力向上","factor":"发布10条非转发主帖,其中5条获得他人回复或点赞","iconColor":"3C9E83","bgColor":"A2F1D9"},"themeCounts":0,"badgeCounts":0,"badges":[],"moderator":false,"superModerator":false,"manageSymbols":null,"badgeLevel":null,"boolIsFan":false,"boolIsHead":false,"favoriteSize":0,"symbols":null,"coverImage":null,"realNameVerified":"success","userBadges":[{"badgeId":"1026c425416b44e0aac28c11a0848493-2","templateUuid":"1026c425416b44e0aac28c11a0848493","name":"Senior Tiger","description":"Join the tiger community for 1000 days","bigImgUrl":"https://static.tigerbbs.com/0063fb68ea29c9ae6858c58630e182d5","smallImgUrl":"https://static.tigerbbs.com/96c699a93be4214d4b49aea6a5a5d1a4","grayImgUrl":"https://static.tigerbbs.com/35b0e542a9ff77046ed69ef602bc105d","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2024.02.05","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1001},{"badgeId":"7a9f168ff73447fe856ed6c938b61789-1","templateUuid":"7a9f168ff73447fe856ed6c938b61789","name":"Knowledgeable Investor","description":"Traded more than 10 stocks","bigImgUrl":"https://static.tigerbbs.com/e74cc24115c4fbae6154ec1b1041bf47","smallImgUrl":"https://static.tigerbbs.com/d48265cbfd97c57f9048db29f22227b0","grayImgUrl":"https://static.tigerbbs.com/76c6d6898b073c77e1c537ebe9ac1c57","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2021.12.21","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1102},{"badgeId":"a83d7582f45846ffbccbce770ce65d84-1","templateUuid":"a83d7582f45846ffbccbce770ce65d84","name":"Real Trader","description":"Completed a transaction","bigImgUrl":"https://static.tigerbbs.com/2e08a1cc2087a1de93402c2c290fa65b","smallImgUrl":"https://static.tigerbbs.com/4504a6397ce1137932d56e5f4ce27166","grayImgUrl":"https://static.tigerbbs.com/4b22c79415b4cd6e3d8ebc4a0fa32604","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2021.12.21","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1100},{"badgeId":"972123088c9646f7b6091ae0662215be-1","templateUuid":"972123088c9646f7b6091ae0662215be","name":"Elite Trader","description":"Total number of securities or futures transactions reached 30","bigImgUrl":"https://static.tigerbbs.com/ab0f87127c854ce3191a752d57b46edc","smallImgUrl":"https://static.tigerbbs.com/c9835ce48b8c8743566d344ac7a7ba8c","grayImgUrl":"https://static.tigerbbs.com/76754b53ce7a90019f132c1d2fbc698f","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2021.12.21","exceedPercentage":"60.03%","individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1100}],"userBadgeCount":4,"currentWearingBadge":null,"individualDisplayBadges":null,"crmLevel":2,"crmLevelSwitch":0,"location":null,"starInvestorFollowerNum":0,"starInvestorFlag":false,"starInvestorOrderShareNum":0,"subscribeStarInvestorNum":0,"ror":null,"winRationPercentage":null,"showRor":false,"investmentPhilosophy":null,"starInvestorSubscribeFlag":false},"baikeInfo":{},"tab":"post","tweets":[{"id":886904252,"gmtCreate":1631542060176,"gmtModify":1676530570995,"author":{"id":"3582675299947074","authorId":"3582675299947074","name":"JessLi","avatar":"https://static.tigerbbs.com/4825402e4b1dc6309048cc8a1269b652","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3582675299947074","authorIdStr":"3582675299947074"},"themes":[],"htmlText":"You really shouldn't spread false news","listText":"You really shouldn't spread false news","text":"You really shouldn't spread false news","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":1,"repostSize":0,"link":"https://ttm.financial/post/886904252","repostId":"886070662","repostType":1,"isVote":1,"tweetType":1,"viewCount":497,"authorTweetTopStatus":1,"verified":2,"comments":[{"author":{"id":"3574968450404111","authorId":"3574968450404111","name":"Bloomberg Markets","avatar":"https://community-static.tradeup.com/news/f516c34a4c299ef7bfa6036707b67c4a","crmLevel":8,"crmLevelSwitch":1,"idStr":"3574968450404111","authorIdStr":"3574968450404111"},"content":"I am not. These are facts. If you cant accept facts then continue to lose money. Its your money anyways.","text":"I am not. These are facts. If you cant accept facts then continue to lose money. Its your money anyways.","html":"I am not. These are facts. If you cant accept facts then continue to lose money. Its your money anyways."}],"imageCount":0,"langContent":"EN","totalScore":0},{"id":812236711,"gmtCreate":1630589805833,"gmtModify":1676530348795,"author":{"id":"3582675299947074","authorId":"3582675299947074","name":"JessLi","avatar":"https://static.tigerbbs.com/4825402e4b1dc6309048cc8a1269b652","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3582675299947074","authorIdStr":"3582675299947074"},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/SPLK\">$Splunk(SPLK)$</a>&nbsp;To the MOON","listText":"<a href=\"https://laohu8.com/S/SPLK\">$Splunk(SPLK)$</a>&nbsp;To the MOON","text":"$Splunk(SPLK)$ To the MOON","images":[{"img":"https://static.tigerbbs.com/e0f2ac860e5c5af48b210a561d116654","width":"1080","height":"1920"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":1,"repostSize":0,"link":"https://ttm.financial/post/812236711","isVote":1,"tweetType":1,"viewCount":868,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"EN","totalScore":0},{"id":160094149,"gmtCreate":1623765946981,"gmtModify":1703818727167,"author":{"id":"3582675299947074","authorId":"3582675299947074","name":"JessLi","avatar":"https://static.tigerbbs.com/4825402e4b1dc6309048cc8a1269b652","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3582675299947074","authorIdStr":"3582675299947074"},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/HMG\">$HMG/Courtland Properties(HMG)$</a>&nbsp; just IPO? No volume but so much change","listText":"<a href=\"https://laohu8.com/S/HMG\">$HMG/Courtland Properties(HMG)$</a>&nbsp; just IPO? No volume but so much change","text":"$HMG/Courtland Properties(HMG)$ just IPO? No volume but so much change","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/160094149","isVote":1,"tweetType":1,"viewCount":448,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":187482419,"gmtCreate":1623762016731,"gmtModify":1703818485362,"author":{"id":"3582675299947074","authorId":"3582675299947074","name":"JessLi","avatar":"https://static.tigerbbs.com/4825402e4b1dc6309048cc8a1269b652","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3582675299947074","authorIdStr":"3582675299947074"},"themes":[],"htmlText":"Buy or nor","listText":"Buy or nor","text":"Buy or nor","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/187482419","repostId":"1178091722","repostType":4,"repost":{"id":"1178091722","weMediaInfo":{"introduction":"Providing stock market headlines, business news, financials and earnings ","home_visible":1,"media_name":"Tiger Newspress","id":"1079075236","head_image":"https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba"},"pubTimestamp":1623757022,"share":"https://ttm.financial/m/news/1178091722?lang=&edition=fundamental","pubTime":"2021-06-15 19:37","market":"us","language":"en","title":"Ocugen Secures Manufacturing Partnership for US Production of COVID-19 Vaccine Candidate, COVAXIN™","url":"https://stock-news.laohu8.com/highlight/detail?id=1178091722","media":"Tiger Newspress","summary":"Ocugen, Inc.(NASDAQ: OCGN), a biopharmaceutical company focused on discovering, developing, and comm","content":"<p></p>\n<p><img src=\"https://static.tigerbbs.com/30195a620eedea62e516df9d39d4d93b\" tg-width=\"663\" tg-height=\"440\">Ocugen, Inc.(NASDAQ: OCGN), a biopharmaceutical company focused on discovering, developing, and commercializing gene therapies to cure blindness diseases and developing a vaccine to save lives from COVID-19, today announced that it has selected Jubilant HollisterStier of Spokane, Washington as its manufacturing partner forCOVAXIN™to prepare for potential commercial manufacturing of COVAXIN™ for the US and Canadian markets.</p>\n<p>“We are fully committed to bringing COVAXIN to the US and Canadian markets because we believe it has the potential to save lives by adding a weapon to the arsenal in the fight against emerging variants,” saidJ.P. Gabriel, Ocugen’s Senior Vice President, Manufacturing and Supply Chain. “Securing US-based manufacturing capability is a critical step as we prepare to submit our regulatory submissions to the FDA and Health Canada. Based on Bharat Biotech’s strong track record of developing and commercializing vaccines globally and Jubilant’s proven track record in manufacturing, we are well-prepared to transition US manufacturing of COVAXIN to our new partner.”</p>\n<p>“We are excited to expand our basket of vaccine products and meet the increasing demand from our customers for COVID-19 vaccines in the US,” said Amit Arora, President Jubilant HollisterStier.</p>\n<p>“We are pleased to partner with Ocugen and support the ongoing fight against COVID-19. With two facilities in North America working to manufacture multiple COVID-19 vaccines and therapies, we remain committed to supporting efforts to eradicate this global pandemic,” stated Pramod Yadav, CEO Jubilant Pharma Limited.</p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Ocugen Secures Manufacturing Partnership for US Production of COVID-19 Vaccine Candidate, COVAXIN™</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nOcugen Secures Manufacturing Partnership for US Production of COVID-19 Vaccine Candidate, COVAXIN™\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1079075236\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Tiger Newspress </p>\n<p class=\"h-time\">2021-06-15 19:37</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p></p>\n<p><img src=\"https://static.tigerbbs.com/30195a620eedea62e516df9d39d4d93b\" tg-width=\"663\" tg-height=\"440\">Ocugen, Inc.(NASDAQ: OCGN), a biopharmaceutical company focused on discovering, developing, and commercializing gene therapies to cure blindness diseases and developing a vaccine to save lives from COVID-19, today announced that it has selected Jubilant HollisterStier of Spokane, Washington as its manufacturing partner forCOVAXIN™to prepare for potential commercial manufacturing of COVAXIN™ for the US and Canadian markets.</p>\n<p>“We are fully committed to bringing COVAXIN to the US and Canadian markets because we believe it has the potential to save lives by adding a weapon to the arsenal in the fight against emerging variants,” saidJ.P. Gabriel, Ocugen’s Senior Vice President, Manufacturing and Supply Chain. “Securing US-based manufacturing capability is a critical step as we prepare to submit our regulatory submissions to the FDA and Health Canada. Based on Bharat Biotech’s strong track record of developing and commercializing vaccines globally and Jubilant’s proven track record in manufacturing, we are well-prepared to transition US manufacturing of COVAXIN to our new partner.”</p>\n<p>“We are excited to expand our basket of vaccine products and meet the increasing demand from our customers for COVID-19 vaccines in the US,” said Amit Arora, President Jubilant HollisterStier.</p>\n<p>“We are pleased to partner with Ocugen and support the ongoing fight against COVID-19. With two facilities in North America working to manufacture multiple COVID-19 vaccines and therapies, we remain committed to supporting efforts to eradicate this global pandemic,” stated Pramod Yadav, CEO Jubilant Pharma Limited.</p>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"OCGN":"Ocugen"},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1178091722","content_text":"Ocugen, Inc.(NASDAQ: OCGN), a biopharmaceutical company focused on discovering, developing, and commercializing gene therapies to cure blindness diseases and developing a vaccine to save lives from COVID-19, today announced that it has selected Jubilant HollisterStier of Spokane, Washington as its manufacturing partner forCOVAXIN™to prepare for potential commercial manufacturing of COVAXIN™ for the US and Canadian markets.\n“We are fully committed to bringing COVAXIN to the US and Canadian markets because we believe it has the potential to save lives by adding a weapon to the arsenal in the fight against emerging variants,” saidJ.P. Gabriel, Ocugen’s Senior Vice President, Manufacturing and Supply Chain. “Securing US-based manufacturing capability is a critical step as we prepare to submit our regulatory submissions to the FDA and Health Canada. Based on Bharat Biotech’s strong track record of developing and commercializing vaccines globally and Jubilant’s proven track record in manufacturing, we are well-prepared to transition US manufacturing of COVAXIN to our new partner.”\n“We are excited to expand our basket of vaccine products and meet the increasing demand from our customers for COVID-19 vaccines in the US,” said Amit Arora, President Jubilant HollisterStier.\n“We are pleased to partner with Ocugen and support the ongoing fight against COVID-19. With two facilities in North America working to manufacture multiple COVID-19 vaccines and therapies, we remain committed to supporting efforts to eradicate this global pandemic,” stated Pramod Yadav, CEO Jubilant Pharma Limited.","news_type":1},"isVote":1,"tweetType":1,"viewCount":427,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":188033184,"gmtCreate":1623415452748,"gmtModify":1704202986396,"author":{"id":"3582675299947074","authorId":"3582675299947074","name":"JessLi","avatar":"https://static.tigerbbs.com/4825402e4b1dc6309048cc8a1269b652","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3582675299947074","authorIdStr":"3582675299947074"},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/ANVS\">$Annovis Bio, Inc.(ANVS)$</a>&nbsp;lets go to 100 today!&nbsp;","listText":"<a href=\"https://laohu8.com/S/ANVS\">$Annovis Bio, Inc.(ANVS)$</a>&nbsp;lets go to 100 today!&nbsp;","text":"$Annovis Bio, Inc.(ANVS)$ lets go to 100 today!","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":5,"commentSize":2,"repostSize":0,"link":"https://ttm.financial/post/188033184","isVote":1,"tweetType":1,"viewCount":958,"authorTweetTopStatus":1,"verified":2,"comments":[{"author":{"id":"3494316846485147","authorId":"3494316846485147","name":"一买就暴跌","avatar":"https://static.tigerbbs.com/99886dc19e57b6a1d36e0c23ae32d91a","crmLevel":7,"crmLevelSwitch":0,"idStr":"3494316846485147","authorIdStr":"3494316846485147"},"content":"No, it should be 200","text":"No, it should be 200","html":"No, it should be 200"}],"imageCount":0,"langContent":"EN","totalScore":0},{"id":180087370,"gmtCreate":1623164605890,"gmtModify":1704197526867,"author":{"id":"3582675299947074","authorId":"3582675299947074","name":"JessLi","avatar":"https://static.tigerbbs.com/4825402e4b1dc6309048cc8a1269b652","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3582675299947074","authorIdStr":"3582675299947074"},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/CLNE\">$Clean Energy Fuels(CLNE)$</a>&nbsp;time to go","listText":"<a href=\"https://laohu8.com/S/CLNE\">$Clean Energy Fuels(CLNE)$</a>&nbsp;time to go","text":"$Clean Energy Fuels(CLNE)$ time to go","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/180087370","isVote":1,"tweetType":1,"viewCount":293,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":114561798,"gmtCreate":1623080444814,"gmtModify":1704195736037,"author":{"id":"3582675299947074","authorId":"3582675299947074","name":"JessLi","avatar":"https://static.tigerbbs.com/4825402e4b1dc6309048cc8a1269b652","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3582675299947074","authorIdStr":"3582675299947074"},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/ANVS\">$Annovis Bio, Inc.(ANVS)$</a>&nbsp;hoi where is my 80","listText":"<a href=\"https://laohu8.com/S/ANVS\">$Annovis Bio, Inc.(ANVS)$</a>&nbsp;hoi where is my 80","text":"$Annovis Bio, Inc.(ANVS)$ hoi where is my 80","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":5,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/114561798","isVote":1,"tweetType":1,"viewCount":603,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0}],"hots":[{"id":188033184,"gmtCreate":1623415452748,"gmtModify":1704202986396,"author":{"id":"3582675299947074","authorId":"3582675299947074","name":"JessLi","avatar":"https://static.tigerbbs.com/4825402e4b1dc6309048cc8a1269b652","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3582675299947074","authorIdStr":"3582675299947074"},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/ANVS\">$Annovis Bio, Inc.(ANVS)$</a>&nbsp;lets go to 100 today!&nbsp;","listText":"<a href=\"https://laohu8.com/S/ANVS\">$Annovis Bio, Inc.(ANVS)$</a>&nbsp;lets go to 100 today!&nbsp;","text":"$Annovis Bio, Inc.(ANVS)$ lets go to 100 today!","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":5,"commentSize":2,"repostSize":0,"link":"https://ttm.financial/post/188033184","isVote":1,"tweetType":1,"viewCount":958,"authorTweetTopStatus":1,"verified":2,"comments":[{"author":{"id":"3494316846485147","authorId":"3494316846485147","name":"一买就暴跌","avatar":"https://static.tigerbbs.com/99886dc19e57b6a1d36e0c23ae32d91a","crmLevel":7,"crmLevelSwitch":0,"idStr":"3494316846485147","authorIdStr":"3494316846485147"},"content":"No, it should be 200","text":"No, it should be 200","html":"No, it should be 200"}],"imageCount":0,"langContent":"EN","totalScore":0},{"id":114561798,"gmtCreate":1623080444814,"gmtModify":1704195736037,"author":{"id":"3582675299947074","authorId":"3582675299947074","name":"JessLi","avatar":"https://static.tigerbbs.com/4825402e4b1dc6309048cc8a1269b652","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3582675299947074","authorIdStr":"3582675299947074"},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/ANVS\">$Annovis Bio, Inc.(ANVS)$</a>&nbsp;hoi where is my 80","listText":"<a href=\"https://laohu8.com/S/ANVS\">$Annovis Bio, Inc.(ANVS)$</a>&nbsp;hoi where is my 80","text":"$Annovis Bio, Inc.(ANVS)$ hoi where is my 80","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":5,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/114561798","isVote":1,"tweetType":1,"viewCount":603,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":812236711,"gmtCreate":1630589805833,"gmtModify":1676530348795,"author":{"id":"3582675299947074","authorId":"3582675299947074","name":"JessLi","avatar":"https://static.tigerbbs.com/4825402e4b1dc6309048cc8a1269b652","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3582675299947074","authorIdStr":"3582675299947074"},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/SPLK\">$Splunk(SPLK)$</a>&nbsp;To the MOON","listText":"<a href=\"https://laohu8.com/S/SPLK\">$Splunk(SPLK)$</a>&nbsp;To the MOON","text":"$Splunk(SPLK)$ To the MOON","images":[{"img":"https://static.tigerbbs.com/e0f2ac860e5c5af48b210a561d116654","width":"1080","height":"1920"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":1,"repostSize":0,"link":"https://ttm.financial/post/812236711","isVote":1,"tweetType":1,"viewCount":868,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"EN","totalScore":0},{"id":886904252,"gmtCreate":1631542060176,"gmtModify":1676530570995,"author":{"id":"3582675299947074","authorId":"3582675299947074","name":"JessLi","avatar":"https://static.tigerbbs.com/4825402e4b1dc6309048cc8a1269b652","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3582675299947074","authorIdStr":"3582675299947074"},"themes":[],"htmlText":"You really shouldn't spread false news","listText":"You really shouldn't spread false news","text":"You really shouldn't spread false news","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":1,"repostSize":0,"link":"https://ttm.financial/post/886904252","repostId":"886070662","repostType":1,"isVote":1,"tweetType":1,"viewCount":497,"authorTweetTopStatus":1,"verified":2,"comments":[{"author":{"id":"3574968450404111","authorId":"3574968450404111","name":"Bloomberg Markets","avatar":"https://community-static.tradeup.com/news/f516c34a4c299ef7bfa6036707b67c4a","crmLevel":8,"crmLevelSwitch":1,"idStr":"3574968450404111","authorIdStr":"3574968450404111"},"content":"I am not. These are facts. If you cant accept facts then continue to lose money. Its your money anyways.","text":"I am not. These are facts. If you cant accept facts then continue to lose money. Its your money anyways.","html":"I am not. These are facts. If you cant accept facts then continue to lose money. Its your money anyways."}],"imageCount":0,"langContent":"EN","totalScore":0},{"id":180087370,"gmtCreate":1623164605890,"gmtModify":1704197526867,"author":{"id":"3582675299947074","authorId":"3582675299947074","name":"JessLi","avatar":"https://static.tigerbbs.com/4825402e4b1dc6309048cc8a1269b652","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3582675299947074","authorIdStr":"3582675299947074"},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/CLNE\">$Clean Energy Fuels(CLNE)$</a>&nbsp;time to go","listText":"<a href=\"https://laohu8.com/S/CLNE\">$Clean Energy Fuels(CLNE)$</a>&nbsp;time to go","text":"$Clean Energy Fuels(CLNE)$ time to go","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/180087370","isVote":1,"tweetType":1,"viewCount":293,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":160094149,"gmtCreate":1623765946981,"gmtModify":1703818727167,"author":{"id":"3582675299947074","authorId":"3582675299947074","name":"JessLi","avatar":"https://static.tigerbbs.com/4825402e4b1dc6309048cc8a1269b652","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3582675299947074","authorIdStr":"3582675299947074"},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/HMG\">$HMG/Courtland Properties(HMG)$</a>&nbsp; just IPO? No volume but so much change","listText":"<a href=\"https://laohu8.com/S/HMG\">$HMG/Courtland Properties(HMG)$</a>&nbsp; just IPO? No volume but so much change","text":"$HMG/Courtland Properties(HMG)$ just IPO? No volume but so much change","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/160094149","isVote":1,"tweetType":1,"viewCount":448,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":187482419,"gmtCreate":1623762016731,"gmtModify":1703818485362,"author":{"id":"3582675299947074","authorId":"3582675299947074","name":"JessLi","avatar":"https://static.tigerbbs.com/4825402e4b1dc6309048cc8a1269b652","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3582675299947074","authorIdStr":"3582675299947074"},"themes":[],"htmlText":"Buy or nor","listText":"Buy or nor","text":"Buy or nor","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/187482419","repostId":"1178091722","repostType":4,"repost":{"id":"1178091722","weMediaInfo":{"introduction":"Providing stock market headlines, business news, financials and earnings ","home_visible":1,"media_name":"Tiger Newspress","id":"1079075236","head_image":"https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba"},"pubTimestamp":1623757022,"share":"https://ttm.financial/m/news/1178091722?lang=&edition=fundamental","pubTime":"2021-06-15 19:37","market":"us","language":"en","title":"Ocugen Secures Manufacturing Partnership for US Production of COVID-19 Vaccine Candidate, COVAXIN™","url":"https://stock-news.laohu8.com/highlight/detail?id=1178091722","media":"Tiger Newspress","summary":"Ocugen, Inc.(NASDAQ: OCGN), a biopharmaceutical company focused on discovering, developing, and comm","content":"<p></p>\n<p><img src=\"https://static.tigerbbs.com/30195a620eedea62e516df9d39d4d93b\" tg-width=\"663\" tg-height=\"440\">Ocugen, Inc.(NASDAQ: OCGN), a biopharmaceutical company focused on discovering, developing, and commercializing gene therapies to cure blindness diseases and developing a vaccine to save lives from COVID-19, today announced that it has selected Jubilant HollisterStier of Spokane, Washington as its manufacturing partner forCOVAXIN™to prepare for potential commercial manufacturing of COVAXIN™ for the US and Canadian markets.</p>\n<p>“We are fully committed to bringing COVAXIN to the US and Canadian markets because we believe it has the potential to save lives by adding a weapon to the arsenal in the fight against emerging variants,” saidJ.P. Gabriel, Ocugen’s Senior Vice President, Manufacturing and Supply Chain. “Securing US-based manufacturing capability is a critical step as we prepare to submit our regulatory submissions to the FDA and Health Canada. Based on Bharat Biotech’s strong track record of developing and commercializing vaccines globally and Jubilant’s proven track record in manufacturing, we are well-prepared to transition US manufacturing of COVAXIN to our new partner.”</p>\n<p>“We are excited to expand our basket of vaccine products and meet the increasing demand from our customers for COVID-19 vaccines in the US,” said Amit Arora, President Jubilant HollisterStier.</p>\n<p>“We are pleased to partner with Ocugen and support the ongoing fight against COVID-19. With two facilities in North America working to manufacture multiple COVID-19 vaccines and therapies, we remain committed to supporting efforts to eradicate this global pandemic,” stated Pramod Yadav, CEO Jubilant Pharma Limited.</p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Ocugen Secures Manufacturing Partnership for US Production of COVID-19 Vaccine Candidate, COVAXIN™</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nOcugen Secures Manufacturing Partnership for US Production of COVID-19 Vaccine Candidate, COVAXIN™\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1079075236\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Tiger Newspress </p>\n<p class=\"h-time\">2021-06-15 19:37</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p></p>\n<p><img src=\"https://static.tigerbbs.com/30195a620eedea62e516df9d39d4d93b\" tg-width=\"663\" tg-height=\"440\">Ocugen, Inc.(NASDAQ: OCGN), a biopharmaceutical company focused on discovering, developing, and commercializing gene therapies to cure blindness diseases and developing a vaccine to save lives from COVID-19, today announced that it has selected Jubilant HollisterStier of Spokane, Washington as its manufacturing partner forCOVAXIN™to prepare for potential commercial manufacturing of COVAXIN™ for the US and Canadian markets.</p>\n<p>“We are fully committed to bringing COVAXIN to the US and Canadian markets because we believe it has the potential to save lives by adding a weapon to the arsenal in the fight against emerging variants,” saidJ.P. Gabriel, Ocugen’s Senior Vice President, Manufacturing and Supply Chain. “Securing US-based manufacturing capability is a critical step as we prepare to submit our regulatory submissions to the FDA and Health Canada. Based on Bharat Biotech’s strong track record of developing and commercializing vaccines globally and Jubilant’s proven track record in manufacturing, we are well-prepared to transition US manufacturing of COVAXIN to our new partner.”</p>\n<p>“We are excited to expand our basket of vaccine products and meet the increasing demand from our customers for COVID-19 vaccines in the US,” said Amit Arora, President Jubilant HollisterStier.</p>\n<p>“We are pleased to partner with Ocugen and support the ongoing fight against COVID-19. With two facilities in North America working to manufacture multiple COVID-19 vaccines and therapies, we remain committed to supporting efforts to eradicate this global pandemic,” stated Pramod Yadav, CEO Jubilant Pharma Limited.</p>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"OCGN":"Ocugen"},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1178091722","content_text":"Ocugen, Inc.(NASDAQ: OCGN), a biopharmaceutical company focused on discovering, developing, and commercializing gene therapies to cure blindness diseases and developing a vaccine to save lives from COVID-19, today announced that it has selected Jubilant HollisterStier of Spokane, Washington as its manufacturing partner forCOVAXIN™to prepare for potential commercial manufacturing of COVAXIN™ for the US and Canadian markets.\n“We are fully committed to bringing COVAXIN to the US and Canadian markets because we believe it has the potential to save lives by adding a weapon to the arsenal in the fight against emerging variants,” saidJ.P. Gabriel, Ocugen’s Senior Vice President, Manufacturing and Supply Chain. “Securing US-based manufacturing capability is a critical step as we prepare to submit our regulatory submissions to the FDA and Health Canada. Based on Bharat Biotech’s strong track record of developing and commercializing vaccines globally and Jubilant’s proven track record in manufacturing, we are well-prepared to transition US manufacturing of COVAXIN to our new partner.”\n“We are excited to expand our basket of vaccine products and meet the increasing demand from our customers for COVID-19 vaccines in the US,” said Amit Arora, President Jubilant HollisterStier.\n“We are pleased to partner with Ocugen and support the ongoing fight against COVID-19. With two facilities in North America working to manufacture multiple COVID-19 vaccines and therapies, we remain committed to supporting efforts to eradicate this global pandemic,” stated Pramod Yadav, CEO Jubilant Pharma Limited.","news_type":1},"isVote":1,"tweetType":1,"viewCount":427,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0}],"lives":[]}